The effects of escitalopram on myocardial apoptosis and the expression of Bax and Bcl-2 during myocardial ischemia/reperfusion in a model of rats with depression

BMC Psychiatry

Volumn 14, Issue 1, 2014, Pages

  Wang, Yiming ^a   Zhang, Hongming ^b   Chai, Fangxian ^a   Liu, Xingde ^c   Berk, Michael ^d,e,f  

^a GUIZHOU MEDICAL UNIVERSITY   (China)

^b JINAN MILITARY GENERAL HOSPITAL   (China)

^c Hospital Affiliated to Medical University Department of Cardiology   (China)

^d DEAKIN UNIVERSITY   (Australia)

^e MONASH UNIVERSITY   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Bax; Bcl 2; Depression; Escitalopram; Myocardial infarction

Indexed keywords

ESCITALOPRAM; PROTEIN BAX; PROTEIN BCL 2; TRIPHENYLTETRAZOLIUM; BAX PROTEIN, RAT; CITALOPRAM;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CHRONIC STRESS; CONTROLLED STUDY; DEPRESSION; DOWN REGULATION; DRUG MECHANISM; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; IMMUNOHISTOCHEMISTRY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; BIOSYNTHESIS; DEPRESSIVE DISORDER, MAJOR; DISEASE MODEL; DRUG EFFECTS; HEART MUSCLE; HUMAN; METABOLISM; MYOCARDIAL REPERFUSION INJURY; PATHOLOGY; PHYSIOLOGY; PSYCHOLOGY; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DISEASE MODELS, ANIMAL; HUMANS; MALE; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME;

EID: 84924019200     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/s12888-014-0349-x     Document Type: Article

References (31)

1. Katon WJ: Epidemiology and treatment of depression in patients with chronic medical illness. Dialogues Clin Neurosci 2011, 13:7-23.
2. Nicholson A, Kuper H, Hemingway H: Depression as an a etiologic and prognostic factor in coronary heart disease:a meta analysis of 6362 events among 146538 participants in 54 observational studies. Eur Heart J 2006, 27:2763-2774.
3. Frasure-Smith N, Lespérance F, Gravel G, Masson A, Juneau M, Talajic M, Bourassa MG: Social support, depression and mortality during the first my cardial infarction. Circulation 2000, 101:1919-1924.
4. Wang Y, Liu X, Zhang D, Chen J, Liu S, Berk M: The effects of apoptosis vulnerability markers on the myocardium in depression after myocardial infarction. BMC Med 2013, 11:32-40.
5. Dioguard P: Off-pump coronary artery bypass grafting in patients with st-segment elevation myocardial infarction. J Cardiovasc Dis Diagn 2013, 2:135-141.
6. Glassman AH, O'Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT Jr, Krishnan KR, van Zyl LT, Swenson JR, Finkel MS, Landau C, Shapiro PA, Pepine CJ, Mardekian J, Harrison WM, Barton D, Mclvor M: Sertraline treatment of major depression in patients with acute MI or unstable Angina. JAMA 2002, 288:701-709.
7. Moreau JL, Jenck F, Martin JR, Mortas P, Haefely WE: Antidepressant treatment prevents chronic unpredictable mild stress-induced anhedonia as assessed by ventral tegmentum self-stimulation behavior in rats. Eur Neuropsychopharmacol 1992, 2:43-49.
8. Willner P, Muscat R, Papp M: Chronic mild stress-induced anhedonia: a realistic animal model of depression. Neurosci Biobehav Rev 1992, 16:525-534.
9. Willner P, Towell A, Sampson D, Sophokleous S, Muscat R: Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology 1987, 93:358-364.
10. Montgomery KS, Mackey J, Thuett K, Ginestra S, Bizon JL, Abbott LC: Chronic, low-dose prenatal exposure to methylmercury impairs motor and mnemonic function in adult C57/B6 mice. Behav Brain Res 2008, 191:55-61.
11. Grippo AJ, Beltz TG, Weiss RM, Johnson AK: The effects of chronic fluoxetine treatment on chronic mild stress-induced cardiovascular changes and anhedonia. Biol Psychiatry 2006, 59:309-316.
12. Henningsen K, Andreasen JT, Bouzinova EV, Jayatissa MN, Jensen MS, Redrobe JP, Wiborg O: Cognitive deficits in the rat chronic mild stress model for depression: relation to anhedonic-like responses. Behav Brain Res 2009, 198:136-141.
13. Wu JC, Chen IY, Wang Y, Tseng JR, Chhabra A, Salek M, Min JJ, Fishbein MC, Crystal R, Gambhir SS: Molecular imaging of the kinetics of vascular endothelial growth factor gene expression in ischemic myocardium. Circulation 2004, 110:685-691.
14. Wehrens XH, Kirchhoff S, Doevendans PA: Mouse electrocardiography: an interval of thirty years. Cardiovasc Res 2000, 45:231-237.
15. Wann BP, Boucher M, Kaloustian S, Nim S, Godbout R, Rousseau G: Apoptosis detected in the amygdala following myocardial infarction in the rat. Biol Psychiat 2006, 59:430-433.
16. Zhang H, Liu L, Huang G, Zhou L, Wu W, Zhang T, Huang H: Protective effect of electroacupuncture at the Neiguan point in a rabbit model of myocardial ischemia-reperfusion injury. Can J Cardiol 2009, 25:359-563.
17. McCully JD, Wakiyama H, Hsieh YJ, Jones M, Levitsky S: Differential contribution of necrosis and apoptosis in myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physol 2004, 286:H1923-H1935.
18. Spoon DB, Psaltis PJ, Singh M, Holmes DR Jr, Gersh BJ, Rihal CS, Lennon RJ, Moussa ID, Simari RD, Gulati R: Trends in cause of death after percutaneous coronary intervention. Circulation 2014, 129:1267-1269.
19. von Känel R, Begré S: Depression after myocardial infarction: unraveling the mystery of poor cardiovascular prognosis and role of beta-blocker therapy. J Am Coll Cardiol 2006, 48:2215-2217.
20. van Melle JP, de Jonge P, Spijkerman TA, Tijssen JG, Ormel J, van Veldhuisen DJ, van den Brink RH, van den Berg MP: Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom Med 2004, 66:814-822.
21. Carney RM, Freedland KE: Depression, mortality, and medical morbidity in patients with coronary heart disease. Biol Psychiat 2003, 54:241-247.
22. Wann BP, Bah TM, Kaloustian S, Boucher M, Dufort AM, Le Marec N, Godbout R, Rousseau G: Behavioural signs of depression and apoptosis in the limbic system following myocardial infarction: effects of sertraline. J Psychopharmacol 2009, 23:451-459.
23. Bah TM, Benderdour M, Kaloustian S, Karam R, Rousseau G, Godbout R: Escitalopram reduces circulating pro-inflammatory cytokines and improves depressive behavior without affecting sleep in a rat model of post-cardiac infarct depression. Behav Brain Res 2011, 225:243-251.
24. Nunez G, Clarke MF: The Bcl-2 family of proteins: regulators of cell death and survival. Trends Cell Biol 1994, 4:399-403.
25. White E: Life, death and the pursuit of apoptosis. Genes Dev 1996, 10:1-15.
26. Vekrellis K, McCarthy MJ, Watson A, Whitfield J, Rubin LL, Ham J: Bax promotes neuronal cell death and is downregulated during the development of the nervous system. Development 1997, 124:1239-1249.
27. Tabas I, Seimon T, Timmins J, Li G, Lim W: Macrophage apoptosis in advanced atherosclerosis. Ann NY Acad Sci 2009, 1173:E40-E45.
28. Sima AV, Stancu CS, Simionescu M: Vascular endothelium in atherosclerosis. Cell Tissue Res 2009, 50:382-387.
29. Bach T, Syversveen T, Kvingedal AM, Krobert KA, Brattelid T, Kaumann AJ, Levy FO: 5HT4(a) and 5-HT4(b) receptors have nearly identical pharmacology and are both expressed in human atrium and ventricle. Naunyn Schmiedebergs Arch Pharmaco 2001, 363:146-160.
30. Groban L, Kitzman DW, Register TC, Shively CA: Effect of depression and sertraline treatment on cardiac function in female nonhuman primates. Psychosom Med 2014, 76:137-146.
31. Jiang W, Velazquez EJ, Kuchibhatla M, Samad Z, Boyle SH, Kuhn C, Becker RC, Ortel TL, Williams RB, Rogers JG, O'Connor C: Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial. JAMA 2013, 309:2139-2149.